The countdown is on! Despite many imponderables and detours, the latest generation broker, Smartbroker+, is about to be launched. As of today, users can explore the future brand world. In the process, the already successfully running Smartbroker was expanded with new functions and optimized according to the latest customer experience requirements, which should attract new, especially younger target groups in the future. On the other hand, the unique selling proposition of the Next Generation Broker will be retained. Like its predecessor, Smartbroker+ combines the extensive product range of traditional brokers with the favorable conditions of a new broker.
After a bitterly cold crypto winter last year with price losses of up to 78% for Bitcoin alone, the asset class has become one of the best performers on the market, with a gain of 90% since the beginning of 2023. Companies from this segment, such as MicroStrategy, Coinbase, Hut 8 Mining and Bit Digital, were able to more than double in this period. In contrast, the German Bitcoin Group, which operates the trading platform for digital currencies, bitcoin.de, with its subsidiary, has some catching up to do. However, the holding company has significantly more substance than comparable competitors.
Short infotainment formats are popular among viewers - for example, before the news or between two movies. The Canadian biotech startup Defence Therapeutics has now been chosen by the series "Viewpoint with Dennis Quaid" as a partner for a series on the opportunities and limitations of biotechnology. For the Company, which is aiming for the Nasdaq, the associated publicity can only be beneficial. What remains decisive, however, is what happens behind the camera. Groundbreaking research is currently underway.
More is better. According to this motto, the innovative cancer specialist Defence Therapeutics has built an extensive patent portfolio in recent years. Here we discuss the areas in which patents have been filed, what options Defence Therapeutics has as a result, and what will be crucial for the Company, which is facing several clinical trials in 2023 in the coming weeks.
The first series of tests under real road conditions went better than expected for the hydrogen innovator based in Vancouver and London, clearly demonstrating the advantages of hydrogen fuel cell-powered light commercial vehicles with a range of over 500 km compared to battery-electric vans and internal combustion engines. Following in the footsteps of fleet management provider Rivus, which is responsible for managing over 120,000 light commercial vehicles and trucks annually, utility company SSE, which currently maintains one of the largest vehicle fleets in the UK, is now entering the test series. If the results continue to confirm the positive trend, First Hydrogen faces a golden future in the billion-dollar market for climate-neutral vehicles.
In times of crisis like now, the urgency in the supply of strategic metals becomes very apparent. Currently, China is the majority owner of these elements, with 70%. With further escalations in Ukraine and global instabilities, access to key resources is essential, as long-established supply routes can be suspended overnight. Rare metals are crucial for various modern technologies, from smartphones to wind turbines and defense equipment. China could impose an export ban on key raw materials to achieve its strategic goals in Taiwan and exclude the West from supply. This is political leverage that can only be softened by consistently building alternatives. Almonty Industries has 4 major tungsten properties in Spain, Portugal and South Korea. Soon the largest mine will go into production.
Cancer specialist Defence Therapeutics has applied for international patent protection for its versatile Accum™ adjuvant technology. This means that the numerous projects the Company is driving forward in parallel thanks to its platform approach will soon receive a "price tag". Specifically, this involves vaccines against various types of cancer, ranging from skin to pancreatic cancer, some of which will soon be transferred to a Phase I study. The same applies to the promising chemotherapeutic AccuTOX™. We discuss the outlook for the CRISPR "gene scissors," which mRNA study will soon deliver results and the state of takeover activity in the industry.
The question is valid. Is it another tale from "One Thousand and One Nights" like in previous years, or will the ambitious US hydrogen company, led by CEO and marketing specialist Andy Marsh, keep its word this time? After the publication of the ambitious growth targets up to the year 2030 on the occasion of the specially organized Analyst Day, the Plug Power share shot up by more than 60% at its peak. This indicates investors still believe in the story of the fuel cell pioneer. However, the next few months will show whether it can be successfully implemented. Blind faith is likely to be clouded once again by a major capital measure.
Curing skin cancer, lymphoma, lung cancer and even pancreatic cancer - the list of promising projects Defence Therapeutics is advancing is long. But despite the wide range of services, Defence Therapeutics' projects go hand in hand. The reason lies in the Accum™ technology, whose platform approach is now protected by the US Patent Office. Below you can find out about the current status of Defence Therapeutics' projects, where the journey may take us in the coming weeks, and in which area Defence Therapeutics could spring a surprise.
Things continue to go like clockwork at hydrogen innovator First Hydrogen. The Vancouver and London-based company reported better-than-expected test results for its hydrogen fuel cell-powered light-duty vehicles under real-world road conditions. The range of 500 km was exceeded. The Company is also making rapid progress in establishing a complete value chain with the production and distribution of green hydrogen. Despite its excellent business performance, the stock of First Hydrogen has experienced a decline in line with the overall industry trend, which may present an attractive entry opportunity from a long-term perspective.